Status:
TERMINATED
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Lead Sponsor:
St. Louis University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Chemotherapy-induced Nausea and Vomiting
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for m...
Detailed Description
This is a Phase 2B double-blind placebo-controlled crossover study evaluating the efficacy of intravenous fosaprepitant for chemotherapy-induced nausea and vomiting in patients undergoing high-dose in...
Eligibility Criteria
Inclusion
- Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- Evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial.
- Subjects who are willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Be at least 18 years of age at the time of informed consent.
- Has a diagnosis of metastatic melanoma or metastatic renal cell carcinoma and who will undergo high-dose interleukin-2 (HD IL-2) therapy
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at Baseline/Day 1 visit. (See Appendix 6 on p. 51, ECOG Performance Status)
- Female of reproductive potential must agree use non-hormonal methods to avoid pregnancy during study participation and for 1 month after last dose of study drug
Exclusion
- Subjects presenting with any of the following will not be included in the study:
- Women who are pregnant or lactating, or planning pregnancy
- Women of childbearing potential who refuse to use non-hormonal methods to avoid pregnancy
- Known hypersensitivity to any component of fosaprepitant or aprepitant
- Have taken pimozide or cisapride \<4 weeks, cytochrome P450 3A4 inducers within 30 days, strong CYP3A4 inhibitors within 7 days, or antiemetics within 48 hours prior to treatment initiation (See Appendix 7 on p. 52 for list of CYP3A4 inducers and strong CYP3A4 inhibitors)
- Have evidence of clinically significant and unstable diseases or conditions such as cardiovascular, immunosuppressive, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities that the investigator thinks may interfere with study participation
- Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before study entry
- Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- Subjects who are investigational site staff members or who are Sponsor employees directly involved in the conduct of the trial.
- A subject who, in the opinion of the investigator or sponsor, will be uncooperative or unable to comply with study procedures.
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 3 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01874119
Start Date
September 1 2013
End Date
December 3 2015
Last Update
June 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Louis University Hospital
St Louis, Missouri, United States, 63101